The first batch of prescriptions trigger HK$49 million equity funding, Peg Bio enters the period of commercialization and value realization.

According to the Securities Times app, innovative drugs often have to overcome multiple barriers such as hospital access, doctor prescriptions, channel coverage, and patient use before they can truly generate commercial value from approval to market. PegBio (02565.HK), a national first-class innovative drug independently developed by Paget Bio, is currently completing this crucial leap.